“The leave nothing behind” strategy


Special Issue Editor

Cardiovascular Research Team, San Carlo Clinic, Milan, Italy; Fondazione Ricerca e Innovazione Cardiovascolare, Milano, Italy
Interests: Percutaneous tricuspid interventions; Conduction disturbances after TAVI; Antithrombotic therapy in TAVI patients; Percutaneous treatment of bicuspid valve

Special Issue Information

Dear Colleagues,

Interventional cardiology is evolving rapidly with an increased need for better results in treatment of coronary artery disease (CAD) which is the leading cause of death worldwide.
The introduction of drug eluting stents (DES) revolutionized treatment of coronary artery disease by reducing the rate of restenosis to 5%-10%. However, the use of DES in complex patients such as diabetic, small vessel disease, long lesions and coronary artery bypass grafting is still associated with higher risk of ISR.
In recent years, drug-coated balloons (DCB) have emerged as a potential alternative to combat restenosis and fulfill the goal of the DES without duplicating the limitations encountered with previously available devices. With currently available paclitaxel and sirolimus balloon coatings DCBs are showing non-inferiority vs DES in different patient settings. However, a major challenge in the management of coronary artery disease is the accurate identification of those patients who will benefit from either DCB or DES and which coating outperforms the other at long term.

CAD has an increasing incidence, prevalence and mortality rate. In light of recent advances in various delivering and coating devices for management of CAD we introduce this series of concise reviews that will focus on the contemporary management of these patients and investigate different approaches of their care.


Dr. Bernardo Cortese

Guest Editor



Cortese’s DEB SCHOOL XII Edition @ Vercelli’s

Advanced Course on Drug-Eluting Balloon use in coronary revascularizations – for believers, and not:

“Who said you always need a stent?”

Corso sponsorizzato da Fondazione Ricerca e Innovazione Cardiovascolare.

22 Giugno 2022 @ Vercelli Palace Hotel
23 Giugno 2022 @ Ospedale Sant’Andrea, Vercelli

We thank Dr Ugo Fabrizio for hosting the XII edition of DEB School.

Programma Scientifico:

Programma DEB SCHOOL_22-23 giugno 2022_Rev.01


EuroPCR 22: EASTBOURNE Registry LBCT interview

 Bernardo Cortese (Fondazione Ricerca e Innovazione Cardiovascolare, IT) discusses the main findings from the EASTBOURNE Study, that investigated the sirolimus-coated balloon in an all-comer population.

Findings are positive as regards the device’s safety and efficacy profile, with the primary endpoint of target lesion revascularization (TLR) occurring in 6% of the population.

Full interview available here:



EuroPCR 2022 – First Symposium- Current Role of Paclitaxel-DCB in PCI

Fondazione RIC is inviting you.

It is a real pleasure and honor, to share and invite you at the first co-sponsorized symposium on paclitaxel DCB, during EuroPCR 2022. The Course will have the top-in-class Experts on the DCB technology, and will be held in ROOM 252B, Wednesday 18th, 16.30-17.30. Join us if you are attending this years’ EuroPCR!

Home – Fondazione RIC



Course Programme @ https://bit.ly/3OY2nkw